Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation develops and markets advanced therapies for sports medicine and severe burn care, with U.S. commercial products that include MACI, Epicel and NexoBrid. News about VCEL commonly covers financial results, MACI procedure and surgeon activity, burn care revenue trends, and manufacturing capacity for cell therapy products.
Company updates also include regulatory and operational milestones, such as FDA approval of commercial MACI manufacturing at Vericel's advanced therapy facility, as well as BARDA-supported procurement and development activities for NexoBrid. The recurring themes center on commercialization, specialty biologics supply, product access and development within Vericel's cellular therapy portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.